The AI Revolution in Drug Discovery: From Computational Innovation to Clinical Translation

Abstract

Artificial intelligence (AI) has rapidly evolved from a computational research tool into a major driver of innovation across the pharmaceutical development pipeline. Advances in deep learning, foundation models, protein structure prediction, and generative molecular design have accelerated target identification, compound optimization, toxicity prediction, and biomarker discovery. These developments have substantially reduced the time required to generate and prioritize therapeutic hypotheses. Despite this remarkable progress, the translation of computational predictions into clinically effective medicines remains challenging. Drug development continues to be limited by biological complexity, patient heterogeneity, incomplete datasets, and the need for rigorous experimental and clinical validation. AI can improve decision-making, but it cannot replace the biological evidence required for regulatory approval or patient care. This editorial discusses the evolving role of AI in modern drug discovery while highlighting the importance of explainable algorithms, high-quality biomedical data, real-world evidence, and interdisciplinary collaboration. Rather than viewing AI as a replacement for scientists, clinicians, or pharmacologists, it should be considered a powerful partner that enhances scientific reasoning and accelerates translational research. The future of pharmaceutical innovation will depend on integrating computational intelligence with experimental pharmacology, clinical medicine, and regulatory science. Responsible implementation—not computational sophistication alone—will determine whether AI ultimately delivers safer, more effective, and more personalized therapies for patients.